Epidermal growth factor receptor expression in squamous cell carcinoma of the hypopharynx.
Expression of the epidermal growth factor receptor (EGFR) has been demonstrated in normal and malignant squamous epithelia. Its presence has been suggested to be important in the pathophysiology and prognosis of epithelial cancers. Archival tumour specimens from 57 patients with squamous cell carcinoma of the hypopharynx were studied using OM-11-951, a new murine anti-EGFR monoclonal antibody which recognizes the receptor on deparaffinized tissue. By visual inspection, 28 (49%) tumours were EGFR negative; 29 (51%) tumours were EGFR positive. While patients whose tumours were EGFR positive were younger, there was no significant correlation with other clinical or pathological variables (including grade and stage). Patients whose tumours were EGFR negative had a median survival of 21 (95% CI 4.3-37.7) months compared with a median survival of 17 (95% CI 11.4-22) months for patients whose tumours were EGFR positive. The difference was not statistically significant. A multiple regression analysis did not demonstrate EGFR status to be important in predicting survival. These data cast doubt on the prognostic significance of EGFR expression in this neoplasm.
Frank
J L
JL
Department of Surgery, Baystate Medical Center, Tufts University School of Medicine, Springfield, MA 01199.
Garb
J L
JL
Banson
B B
BB
Peterman
J
J
Neifeld
J P
JP
Kay
S
S
Kornstein
M J
MJ
Sismanis
A
A
Ware
J L
JL
D000911:Antibodies, Monoclonal; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D066246:ErbB Receptors / Q000276:immunology / Q000378:metabolism*; D005260:Female; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D015996:Survival Rate
D000911:Antibodies, Monoclonal; D066246:ErbB Receptors